Novartis

Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance

Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...

Novartis Pharma AG: Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance

Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
Red State Observer

New Study Undermines PCR Testing Credibility During Pandemic

The COVID-19 narrative has been dealt a significant blow by a groundbreaking study emerging from Germany, challenging the credibility of PCR testing that was heralded as the cornerstone of pandemic ...
IEEE

Video Streaming Protocols Comparison in Field Experiments for Aerial Teleoperation

Abstract: As aerial robots evolve to perform complex tasks such as manipulation and visual inspection, maintaining the pilot at the center of decision-making is critical for mission safety and ...